Market Overview

UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical Ahead of GALNS Data

Related BMRN
BioMarin to Acquire Rights to Phenylketonuria Franchise From Merck Serono for Upfront Payment of €340M, Plus Milestones
Wednesday's After-Hours Movers: PBF Energy, BioMarin Pharmaceutical And More
BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs (Zacks)

Jefferies reiterated its Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN) and raised its price target from $44 to $46.

Jefferies said, "Our experts discussions indicate probability of successful GALNS Ph3 for Morquio A syndrome (MPS IV) at ~60%-85%. If successful, we forecast ~25-30% upside from current levels (& BMRN will likely continue to trade up on additional pipeline potential). BMRN expects GALNS BLA filing in 1Q13, with potentially regulatory approval by 4Q13. We forecast GALNS to turn BMRN to profitability, with peak annual sales potential of ~$500M."

BioMarin Pharmaceutical closed at $38.87 on Tuesday.

Latest Ratings for BMRN

Oct 2015Raymond JamesInitiates Coverage onOutperform
Aug 2015JefferiesMaintainsBuy
Aug 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (BMRN)

Get Benzinga's Newsletters